Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
July 06, 2020 07:55 ET
|
Immunomedics
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy...
Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update
July 02, 2020 16:05 ET
|
Immunomedics
MORRIS PLAINS, N.J., July 02, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in Upcoming Healthcare Conferences
May 28, 2020 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19
May 27, 2020 16:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting
May 13, 2020 17:01 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in BofA Securities 2020 Health Care Conference
May 07, 2020 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update
May 06, 2020 16:00 ET
|
Immunomedics
Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch ASCENT study...
Immunomedics Announces Commercial Availability of TRODELVY™ in the United States
May 04, 2020 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Closing Of Public Offering Of Common Stock
May 01, 2020 16:05 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 01, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast On May 6, 2020
April 30, 2020 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...